MedTrace Logo

Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy

NCT00349830 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2026-02-10

No results posted yet for this study

Summary

The purpose of this study is to measure the levels of serum proteins and other biomarkers in cancer patients and in patients suspected of having cancer. We believe that some of these markers may be useful for confirming the diagnosis or for selecting patients for specific types of cancer therapies. These markers may also help to predict response to therapy, relapse after therapy, and survival after therapy.

Conditions

  • Carcinomas (Including Squamous Cell and Adenocarcinoma)
  • Neoplasms

Interventions

PROCEDURE

blood draw

Sponsors & Collaborators

Principal Investigators

  • Maximilian Diehn · Stanford University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2002-01-31
Primary Completion
2032-01-31
Completion
2032-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00349830 on ClinicalTrials.gov